Evicenter
P&T meetings

4D-150

Neovascular age-related macular degeneration

Regulatory submission
Not announced
Launch
Not announced
Last updated
180 sources

Company-reported prevalence

4D-150

Overview

FieldValue
Drug4D-150
IndicationNeovascular age-related macular degeneration
DiseaseWet AMD (neovascular age-related macular degeneration, nAMD)
Company4D Molecular Therapeutics (developer; rights outside the Asia-Pacific region, including the United States, Latin America, and Europe); Otsuka Pharmaceutical (licensee; Japan, China, Australia, and other Asia-Pacific markets)
Documents searched4D Molecular Therapeutics website home and pipeline pages (accessed October 2026); 4D Molecular Therapeutics press releases dated April 2023, July 2023, October 2023, December 2023, February 2024, June 2024, July 2024, September 2024, February 2025, March 2025, July 2025, October 2025, November 2025, January 2026, February 2026, June 2026, and July 2026; Form 10-K for 2024 (February 2025); Form 10-K for 2025 (March 2026); Form 10-Q for the quarter ended June 30, 2026 (August 2026); second quarter 2026 results press release (August 2026); corporate presentation (September 2026); scientific congress presentations and posters posted on the 4D Molecular Therapeutics website (2023 to 2026); Otsuka Pharmaceutical press release (October 2025)
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Incidence: 4D Molecular Therapeutics press release, February 2025

“Wet AMD is a highly prevalent disease with estimated incidence rate of 200,000 new patients per year in the United States.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

4D Molecular Therapeutics (2025) press release, February 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Europe

No evidence found.

Global

No evidence found.

Other countries and regions

Number affected: 4D Molecular Therapeutics corporate presentation, September 2026

“~5M prevalence in U.S., Europe, Japan” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2023

4D Molecular Therapeutics (2026) corporate presentation, September 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 8 of 60 (opens in a new tab)

Number affected: 4D Molecular Therapeutics Form 10-K for 2025, March 2026

“Wet AMD is a highly prevalent disease with an estimated 5 million patients affected in the United States, major European markets, and Japan, and is expected to continue growing with the aging global population.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

4D Molecular Therapeutics (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: 4D Molecular Therapeutics press release, February 2025

“It is estimated that the total prevalence of wet AMD in certain major markets, including the United States and the European Union, and Japan, will be greater than 4 million individuals in the next five years.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

4D Molecular Therapeutics (2025) press release, February 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: 4D Molecular Therapeutics press release, October 2023

“It is estimated that the total prevalence of wet AMD in the major markets, including the U.S., EU (major markets), and Japan, is approximately 3.1 million individuals.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

4D Molecular Therapeutics (2023) press release, October 2023, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Prevalence (adults aged 50 and older): Otsuka Pharmaceutical press release, October 2025

“In Japan, approximately 1.3% of individuals aged 50 and older are affected, with nAMD accounting for the majority of cases at 1.2%.” (opens the source at this quote in a new tab)

Cited source: 2.2 Japan Intractable Diseases Information Center 2011

Otsuka Pharmaceutical (2025) press release, October 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: Otsuka Pharmaceutical press release, October 2025

“This corresponds to an estimated patient population in Japan of around 690,000.” (opens the source at this quote in a new tab)

Cited source: 2.2 Japan Intractable Diseases Information Center 2011

Otsuka Pharmaceutical (2025) press release, October 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Geography not stated

Incidence: 4D Molecular Therapeutics corporate presentation, September 2026

“~300K new cases diagnosed annually” (opens the source at this quote in a new tab)

Cited source: 2.1 Market Scope 2023

4D Molecular Therapeutics (2026) corporate presentation, September 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 8 of 60 (opens in a new tab)

Sources the company cites

Market scope 2023

Reference as the company lists it

“Prevalence sourced from Marketscope Retina Market Report 2023.” (opens the source at this quote in a new tab)

4D Molecular Therapeutics (2026) corporate presentation, September 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 8 of 60 (opens in a new tab)

Passage carrying the figure

Not quoted: Proprietary market research report sold by Market Scope, LLC; no public copy exists, and the presentation gives no address for it.

Japan intractable diseases information center 2011

Reference as the company lists it

“https://www.nanbyou.or.jp/entry/2434” (opens the source at this quote in a new tab)

Otsuka Pharmaceutical (2025) press release, October 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

“9年後に行われた再調査では加齢黄斑変性は1.3%（その内、滲出型は1.2%）にみられました。日本全体では、加齢黄斑変性の推定患者数は69万人であり、9年間で約2倍に増加していると推定されます。” (opens the source at this quote in a new tab)

Japan Intractable Diseases Information Center (2011) age-related macular degeneration page, archived November 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

References

  1. 4D Molecular Therapeutics (2023) press release, October 2023 (opens in a new tab)
  2. 4D Molecular Therapeutics (2025) press release, February 2025 (opens in a new tab)
  3. 4D Molecular Therapeutics (2026) corporate presentation, September 2026 (opens in a new tab)
  4. 4D Molecular Therapeutics (2026) Form 10-K for 2025 (opens in a new tab)
  5. Japan Intractable Diseases Information Center (2011) age-related macular degeneration page, archived November 2025 (opens in a new tab)
  6. Otsuka Pharmaceutical (2025) press release, October 2025 (opens in a new tab)